Abstract

Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and monocytes with potent immunosuppressive activity. They are implicated in the regulation of immune responses in many pathological conditions and are closely associated with poor clinical outcomes in cancer. Recent studies have indicated key distinctions between MDSCs and classical neutrophils and monocytes, and, in this Review, we discuss new data on the major genomic and metabolic characteristics of MDSCs. We explain how these characteristics shape MDSC function and could facilitate therapeutic targeting of these cells, particularly in cancer and in autoimmune diseases. Additionally, we briefly discuss emerging data on MDSC involvement in pregnancy, neonatal biology and COVID-19. This Review from Gabrilovich and colleagues discusses our current understanding of the development and functions of myeloid-derived suppressor cells (MDSCs). Recent work has identified unique metabolic properties and gene expression patterns in MDSCs that could help in the development of new therapies for cancer and autoimmunity.

Keywords

Myeloid-derived Suppressor CellSuppressorImmune systemImmunologyMyeloidBiologyMyeloid cellsFunction (biology)Cancer researchCancerMedicineCell biologyGenetics

MeSH Terms

Autoimmune DiseasesCOVID-19CytokinesHumansMonocytesMyeloid CellsMyeloid-Derived Suppressor CellsNeoplasmsNeutrophilsSARS-CoV-2

Affiliated Institutions

Related Publications

Publication Info

Year
2021
Type
review
Volume
21
Issue
8
Pages
485-498
Citations
1561
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1561
OpenAlex
90
Influential

Cite This

Filippo Veglia, Emilio Sanseviero, Dmitry I. Gabrilovich (2021). Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nature reviews. Immunology , 21 (8) , 485-498. https://doi.org/10.1038/s41577-020-00490-y

Identifiers

DOI
10.1038/s41577-020-00490-y
PMID
33526920
PMCID
PMC7849958

Data Quality

Data completeness: 86%